Researchers at Peter MacCallum Cancer Centre have developed a digital phenotype to assist with automatically identifying ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Abivax on Monday night ...

Abivax said on Monday its experimental ulcerative ​colitis drug helped harder-to-treat groups of patients achieve remission, sending ‌U.S.-listed shares of the Paris-based company soaring 26.4% in ...

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with ...

Among biologic-naive patients with moderate to severe ulcerative colitis, upadacitinib and infliximab had the quickest onset ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Disease clearance is the simultaneous achievement of symptomatic, endoscopic and histologic remission. In real-world studies, achieving disease clearance has been associated with reduced rates of ...

A new therapy that combines two existing drugs shows promise for patients with inflammatory bowel disease who have exhausted other treatment options, according to findings from two new trials. Limited ...

Researchers have used machine learning to identify a new antimicrobial peptide that reduces inflammation, restores gut barrier function and reshapes the microbiome in ulcerative colitis. Ulcerative ...

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by recurrent intestinal inflammation, abdominal pain and diarrhea. Although current treatments, including 5-aminosalicylic ...

Among patients with ulcerative colitis (UC), initiation of biologic therapy within 12 months of diagnosis was associated with a significantly reduced risk for disease progression, with no proximal ...